Samarth Kulkarni net worth and biography

Samarth Kulkarni Biography and Net Worth

Dr. Samarth Kulkarni has served as our Chief Executive Officer since 2017. He has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer, and then was appointed to President and Chief Business Officer before becoming CEO. Prior to joining our company, Sam was a Partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice, where he focused on strategy and operations, and led initiatives in areas such as personalized medicine and immunotherapy. Previously, Sam served as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR Therapeutics and Bayer. Sam currently serves on the Board of Directors of two precision oncology companies, Black Diamond Therapeutics and Repare Therapeutics. He also serves on the Board of the Emerging Companies Section of the Biotechnology Innovation Organization (BIO). He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research on the delivery of biological drugs and in the field of molecular diagnostics. He has authored several publications in leading scientific and business journals.

What is Samarth Kulkarni's net worth?

The estimated net worth of Samarth Kulkarni is at least $15.90 million as of November 28th, 2022. Dr. Kulkarni owns 290,279 shares of CRISPR Therapeutics stock worth more than $15,904,386 as of December 1st. This net worth estimate does not reflect any other investments that Dr. Kulkarni may own. Additionally, Dr. Kulkarni receives a salary of $1,180,000.00 as CEO at CRISPR Therapeutics. Learn More about Samarth Kulkarni's net worth.

How old is Samarth Kulkarni?

Dr. Kulkarni is currently 43 years old. There are 4 older executives and no younger executives at CRISPR Therapeutics. Learn More on Samarth Kulkarni's age.

What is Samarth Kulkarni's salary?

As the CEO of CRISPR Therapeutics AG, Dr. Kulkarni earned a total compensation package of $17,037,015.00 in 2021. Dr. Kulkarni earned a salary of $670,000.00, stock awards of $4,819,680.00, options awards of $10,954,947.00, non-equity compensation of $587,925.00, and other compensation of $4,463.00. Learn More on Samarth Kulkarni's salary.

How do I contact Samarth Kulkarni?

The corporate mailing address for Dr. Kulkarni and other CRISPR Therapeutics executives is BAARERSTRASSE 14, ZUG V8, CH-6300. CRISPR Therapeutics can also be reached via phone at (141) 561-3277 and via email at [email protected] Learn More on Samarth Kulkarni's contact information.

Has Samarth Kulkarni been buying or selling shares of CRISPR Therapeutics?

Over the course of the past ninety days, Samarth Kulkarni has sold $2,721,000.00 of CRISPR Therapeutics stock. Most recently, Samarth Kulkarni sold 25,000 shares of the business's stock in a transaction on Monday, November 28th. The shares were sold at an average price of $54.03, for a transaction totalling $1,350,750.00. Following the completion of the sale, the chief executive officer now directly owns 290,279 shares of the company's stock, valued at $15,683,774.37. Learn More on Samarth Kulkarni's trading history.

Who are CRISPR Therapeutics' active insiders?

CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Kurt Emster (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.

Are insiders buying or selling shares of CRISPR Therapeutics?

In the last year, insiders at the sold shares 6 times. They sold a total of 150,000 shares worth more than $9,444,750.00. The most recent insider tranaction occured on November, 28th when CEO Samarth Kulkarni sold 25,000 shares worth more than $1,350,750.00. Insiders at CRISPR Therapeutics own 5.3 % of the company. Learn More about insider trades at CRISPR Therapeutics.

Information on this page was last updated on 11/28/2022.

Samarth Kulkarni Insider Trading History at CRISPR Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/28/2022Sell25,000$54.03$1,350,750.00290,279View SEC Filing Icon  
10/26/2022Sell25,000$54.81$1,370,250.00290,279View SEC Filing Icon  
9/28/2022Sell25,000$64.61$1,615,250.00290,279View SEC Filing Icon  
8/29/2022Sell25,000$66.84$1,671,000.00290,279View SEC Filing Icon  
7/27/2022Sell25,000$75.91$1,897,750.00290,279View SEC Filing Icon  
6/29/2022Sell25,000$61.59$1,539,750.00290,279View SEC Filing Icon  
8/4/2021Sell1,500$125.02$187,530.00189,219View SEC Filing Icon  
6/15/2021Sell30,000$126.43$3,792,900.00217,719View SEC Filing Icon  
1/15/2021Sell20,000$213.67$4,273,400.00202,989View SEC Filing Icon  
12/10/2020Sell20,000$142.29$2,845,800.00189,189View SEC Filing Icon  
6/1/2020Sell17,275$64.68$1,117,347.00188,801View SEC Filing Icon  
5/20/2020Sell10,693$65.28$698,039.04175,833View SEC Filing Icon  
6/17/2019Sell20,000$46.00$920,000.00185,801View SEC Filing Icon  
4/29/2019Sell20,000$42.03$840,600.00186,542View SEC Filing Icon  
6/1/2018Sell15,000$69.36$1,040,400.00163,560View SEC Filing Icon  
8/30/2017Sell27,154$20.08$545,252.32110,893View SEC Filing Icon  
4/27/2017Sell5,481$16.76$91,861.56137,322View SEC Filing Icon  
4/25/2017Sell11,615$16.78$194,899.70137,047View SEC Filing Icon  
See Full Table

Samarth Kulkarni Buying and Selling Activity at CRISPR Therapeutics

This chart shows Samarth Kulkarni's buying and selling at CRISPR Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CRISPR Therapeutics Company Overview

CRISPR Therapeutics logo
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Read More

Today's Range

Now: $53.87
Low: $53.57
High: $55.21

50 Day Range

MA: $57.08
Low: $48.93
High: $66.94

2 Week Range

Now: $53.87
Low: $42.51
High: $86.95

Volume

20,605 shs

Average Volume

957,920 shs

Market Capitalization

$4.22 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71
Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
See This Special Report to Get the Full Story